August 11, 2009
A large effectiveness study comparing Schering-Plough's pegylated-interferon Pegintron and ribavirin with Roche's Pegasys and ribavirin shows both hepatitis C treatments worked equally well.
The study by Dr. Mark Sulkowski of Johns Hopkins University involved 3,000 patients with hepatitis C. Its findings are meant to help guide doctors' decisions about which treatments work best.
"There has been a lot of debate about these two regimens," said Dr. Andrew Muir of Duke University, a co-author of the Schering-Plough-funded study. "It's great to have a study of this size that really answers this question."
Adapted from:
Reuters
07.22.2009; Julie Steenhuysen
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
![]() | Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade |
![]() | CROI 2018: Highlights and What's Next for Advocates |
![]() | Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence |
![]() | Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives |
![]() | Statin Use Might Reduce Risk of Cancer in HIV-Positive People |
![]() | Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say |